Indeed, currently there is only 1 monoclonal antibody on the market to prevent respiratory syncytial virus (RSV) illness in newborns [4]
Indeed, currently there is only 1 monoclonal antibody on the market to prevent respiratory syncytial virus (RSV) illness in newborns [4]. In recent years, with the development of the Cerpegin monoclonal antibody technology, serotherapy has found novel applications in the field of chronic inflammatory and autoimmune diseases and in cancer. immunoglobulins (Igs) isolated from hyper immune sera of animal or human being source can confer immediate safety against pathogens or toxins. This practice, launched by von Behring and Kitasato in 1901 [1], has been extensively used in a prophylactic or restorative establishing [2, 3]. However, polyclonal sera have several problems, such as the use of heterologous proteins, the difficulty of finding immune donors and the risks related to the use of human being blood products. Monoclonal antibodies represent the ideal…